View Future GrowthAnteris Technologies Global 過去の業績過去 基準チェック /06Anteris Technologies Globalの収益は年間平均-37.7%の割合で減少していますが、 Medical Equipment業界の収益は年間 増加しています。収益は年間15.7% 21.6%割合で 減少しています。主要情報-37.68%収益成長率-6.18%EPS成長率Medical Equipment 業界の成長8.90%収益成長率-21.62%株主資本利益率-34.19%ネット・マージン-5,148.78%前回の決算情報31 Mar 2026最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Jun 29+ 5 more updatesAnteris Technologies Global Corp.(NasdaqGM:AVR) dropped from Russell Microcap Growth Benchmark IndexAnteris Technologies Global Corp.(NasdaqGM:AVR) dropped from Russell Microcap Growth Benchmark IndexBoard Change • Jun 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Gregory Moss was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jun 09Anteris Technologies Global Corp. Receives French Regulatory Clearance for Duravr Transcatheter Heart Valve Global Pivotal TrialAnteris Technologies Global Corp. had received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) for the DurAVR Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calcific aortic stenosis (the PARADIGM Trial). This authorization marks a significant milestone in the Company’s clinical and regulatory strategy and enables patient recruitment to commence at centers in France. The Company continues to advance its global clinical strategy, with ongoing site activations and patient enrollment across the United States and Europe. The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR Transcatheter Heart Valve compared to commercially available transcatheter aortic valve replacements (TAVRs). This head-to-head study will enroll approximately 1,000 patients in the ‘All Comers Randomized Cohort’ with 1:1 randomization of patients who will receive either the DurAVR THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure. Anteris’ lead product, the DurAVR THV, was designed in collaboration with interventional cardiologists and cardiac surgeons to treat aortic stenosis – a condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT tissue, Anteris’ patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR Delivery System.お知らせ • May 23Anteris Technologies Global Corp. has filed a Follow-on Equity Offering in the amount of $250 million.Anteris Technologies Global Corp. has filed a Follow-on Equity Offering in the amount of $250 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • May 14Anteris Technologies Global Corp. Appoint Board of DirectorAnteris Technologies Global Corp. announced the appointment of Ms. Susan Knight and Mr. Stephen Denaro to serve on the Board of Directors. Ms. Knight will serve as a Class I Director, with a term expiring at the Company's 2028 annual meeting of stockholders and will serve on the Audit and Risk Committee of the Board. Mr. Denaro will serve as a Class II Director, with a term expiring at the Company’s 2026 annual meeting of stockholders. Ms. Knight most recently served as the Board Chair of Surmodics Inc., a medical device provider, a position she held from 2015 until November 2025. She has served on corporate boards of directors since 2008 and has broad audit committee experience, including serving as committee chair at Surmodics Inc., Greater Metropolitan Housing Corporation and Plato Learning. During her professional career, Ms. Knight was the Senior Vice President and Chief Financial Officer of MTS Systems Corporation from 2011 to 2014 and its Chief Financial Officer from 2001 to 2011. Prior to MTS Systems Corporation, Ms. Knight was the Vice President of Finance of the Home and Building Control Business of Honeywell Inc. from 1994 to 2001. She also held various other management and executive financial positions during her 24-year career at Honeywell Inc. Ms. Knight earned a BSBA in Accounting from Creighton University. Mr. Denaro rejoins the Board with deep knowledge of the Company and its strategic priorities. Together these appointments reinforce the Company’s governance and strategic capabilities as it advances its global clinical and commercial objectives towards the anticipated U.S. and EMA licensure of the DurAVR THV for patients with aortic stenosis.お知らせ • May 06Anteris Technologies Global Corp. Announces First U.S. Patients Treated in Global Pivotal Paradigm TrialAnteris Technologies Global Corp. announced that the first patients in the United States have been enrolled and successfully treated in the DurAVR Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the PARADIGM Trial). The procedures were performed at Montefiore Medical Center, New York, United States. The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR THV compared to commercially available transcatheter aortic valve replacements (TAVRs). This head-to-head study will enroll approximately 1,000 patients in the ‘All Comers Randomized Cohort’ with 1:1 randomization of patients who will receive either the DurAVR THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure. Anteris’ lead product, the DurAVR THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT tissue, Anteris’ patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR Delivery System.お知らせ • Apr 29Anteris Technologies Global Corp. Secures Cms Reimbursement Eligibility for Paradigm TrialAnteris Technologies Global Corp. announced it has secured U.S. Medicare reimbursement eligibility for the global pivotal PARADIGM Trial under a Centers for Medicare & Medicaid Services (CMS) national coverage policy. Eligible procedures performed at participating U.S. study sites are covered under the Transcatheter Aortic Valve Replacement (TAVR) National Coverage Determination 20.32. The CMS framework operates under a Coverage with Evidence Development (CED) model, enabling reimbursement with clinical evidence generation in the PARADIGM Trial. The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR® Transcatheter Heart Valve (THV) compared to commercially available transcatheter aortic valve replacements (TAVRs). This head-to-head study will enroll approximately 1,000 patients in the ‘All Comers Randomized Cohort’ with 1:1 randomization of patients who will receive either the DurAVR® THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure. Anteris’ lead product, the DurAVR® THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.Seeking Alpha • Apr 23Anteris Technologies Looks Bullish If DurAVR's PARADIGM DeliversSummary Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in over 130 patients. AVR’s PARADIGM pivotal trial is the central catalyst. This will compare DurAVR against commercial valves across 85 sites in the US, Europe, and Canada. I believe that Medtronic’s 16.2% stake also offers strategic validation of AVR’s underlying valve technology. And, after AVR’s recent raises, its balance sheet seems well capitalized despite ongoing cash burn. AVR remains speculative until they receive full regulatory approvals. But I feel the upside potential justifies those risks in the long run. Read the full article on Seeking Alphaお知らせ • Jan 22Anteris Technologies Global Corp. has completed a Follow-on Equity Offering in the amount of $200.000002 million.Anteris Technologies Global Corp. has completed a Follow-on Equity Offering in the amount of $200.000002 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 34,782,609 Price\Range: $5.75 Discount Per Security: $0.29325お知らせ • Jan 21+ 1 more updateAnteris Technologies Global Corp. has filed a Follow-on Equity Offering in the amount of $319.999995 million.Anteris Technologies Global Corp. has filed a Follow-on Equity Offering in the amount of $319.999995 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 55,652,173 Price\Range: $5.75 Discount Per Security: $0.29325お知らせ • Dec 15Anteris Technologies Global Corp. Announces Resignation of Stephen Denaro from the Board of DirectorsAnteris Technologies Global Corp. announced on December 14, 2025, Mr. Stephen Denaro resigned from the Board of Directors (the "Board") of Anteris Technologies Global Corp. (the "Company") and as a Class II director with immediate effect. The resignation from the Board was not due to any disagreement with the Company or its management with respect to any matter relating to the Company's operations, policies or practices. Mr. Denaro will continue to serve as the corporate secretary of Anteris Technologies Pty Ltd. ("ATPL") and as a member of the Board of Directors of ATPL and the Company's other Australian subsidiaries.お知らせ • Nov 18Anteris Technologies Global Corp. Presents Data from 100 DurAVR®? THV Patients at PCR London ValvesAnteris Technologies Global Corp. released 30-day clinical outcomes for the DurAVR®? THV in one hundred severe aortic stenosis patients with small aortic annuli (aortic annulus area 404 +- 37mm2). TheDurAVR®? THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality, with 97% freedom from moderate or severe paravalvulvular leak (PPM) in a cohort of small annuli patients similar to the one reported in the SMART Trial1. 30-day Results Highlights for 100 DurAVR®?THV Patients: DurAVR®? TH V delivered a favorable hemodynamic profile with a large EOA of 2.2 +- 0.3 cm2 and a single digit mean pressure gradient (MPG) of 8.2 +- 3.1 mmHg. At 30-days, clinical safety outcomes were positive with no valve related mortality and no moderate or severe paravalVular leak (PVL). Prosthesis-patient mismatch was just 3.0% compared with 11.2% to 35.3% for current commercial devices, highlighting a meaningful reduction in a key predictor of valve failure and disease progression. Hahn RT, Pibarot P. Prosthesis-patient mismatch in transcatheter and surgical aortic valve replacement.お知らせ • Nov 06Anteris Technologies Global Corp. has completed a Follow-on Equity Offering in the amount of AUD 20.91048 million.Anteris Technologies Global Corp. has completed a Follow-on Equity Offering in the amount of AUD 20.91048 million. Security Name: CHESS Depositary Interests Security Type: Depositary Receipt (Common Stock) Securities Offered: 2,788,064 Price\Range: AUD 7.5 Discount Per Security: AUD 0.45 Security Features: Attached Warrants Transaction Features: Regulation S; Subsequent Direct Listingお知らせ • Nov 04FDA Approves Anteris Technologies Global Corp.'s DurAVR®? THV Global Pivotal TrialAnteris Technologies Global Corp. announced it has received U.S. Food and Drug Administration (FDA) approval to initiate PARADIGM, its global Investigational Device Exemption (IDE) clinical trial which is designed to evaluate the DurAVR®? Transcatheter Heart Valve (THV) in patients with severe calcific aortic stenosis and to support a future PMA submission. The PARADIGM Trial is co-chaired by Dr. Michael J. Reardon, Allison Family Distinguished Chair of Cardiovascular Research and Professor of Cardiothoracic Surgery at the Houston Methodist Hospital, Texas and Professor Stephan Windecker, Chairman of the Department of Cardiology at Bern University Hospital, Switzerland. The PARADIGM trial is a prospective randomized controlled trial (RCT) which will evaluate the safety and effectiveness of the DurAVR®? THV compared to commercially available transcatheter aortic valve replacements (TAVRs). This head-to-head study will enroll approximately 1000 patients across the Unites States, Europe and Canada in the 'All Comers Randomized Cohort' with 1:1 randomization of patients who will receive either the DurAVR®?THV or TAVR®? using commercially available and approved THVs. The PARADigM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure. The PARADIGM trials is designed to provide the robust clinical evidence required to support an application to the FDA for Premarket Approval in the United States, with CE Mark approval anticipated to progress in parallel to the PMA. A Premarket Approval (PMA) application requires a high level of clinical evidence to demonstrate reasonable assurance of safety and effectiveness for the intended use. Randomized controlled trials are generally considered Level 1 evidence, the highest level for determining the effectiveness of interventions in evidence-based medicine given RCTs minimize bias and allow a clear comparison between treatment groups.お知らせ • Oct 29Anteris Technologies Global Corp. Announces One-Year Clinical Outcomes for the DurAVR Transcatheter Heart ValveAnteris Technologies Global Corp. announced one-year clinical outcomes for the DurAVR®? Transcatheter Heart Valve (THV) in symptomatic severe aortic stenosis patients with small aortic annulus area 396 + 37 mm2). The DurAVR®? THV System demonstrated single digit mean gradients and large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality at one year, with low prosthesis-patient mismatch at 30 days. One-year Results Highlights: DurAVR®?THV delivered a favorable hemodynamic profile sustained to one-year, with an EOA of 2.1 + 0.2 cm2 and a mean pressure gradient (MPG) of 8.6 + 2.6 mmHg. At one-year, clinical safety outcomes were positive with no valve related mortality and no moderate or severe paravalVular leak (PVL). At 30-days, prosthesis-patient mismatch was just 1.5%, compared with 11.2% to 35.3%1 for current commercial devices, highlighting a meaningful reduction in a key predictor of valve failure and disease progression. The pooled cohort included 65 patients with small aortic Annuli implanted with the DurAVR®? TH V from the ongoing EBARK Study and US Early Feasibility Study (EFS). The encouraging clinical outcomes observed to date in over 100 patients implanted with the DurAVR™? THV will be further validated in the Company's recently initiated global pivotal trial (the "PARADIGM Trial"). The PARADIGM Trial (ClinicalTrials.gov ID NCT07194265) is a prospective, randomized controlled trial (RCT) which will evaluate the safety and effectiveness of theDurAVR®? THV compared to commercially available transcatheter aortic valve replacements (TAVRs) in the treatment of severe aortic stenosis. Prosthesis-patient mismatch (PPM) happens when a prosthetic valve, after being implanted, doesn't have a large enough opening (EOA) to accommodate the patient's blood flow needs, based on their body size. The result is higher than expected gradients. PPM affects a significant proportion of transcatheter aortic valves (TAVR) patients, particularly patients with a small aortic annulus and has been associated with impaired long-term survival following surgical aortic valve replacement (SAVR).お知らせ • Oct 28+ 2 more updatesAnteris Technologies Global Corp. announced that it has received $11.499986 million in fundingOn October 27, 2025, Anteris Technologies Global Corp closed the transaction.お知らせ • Oct 16Anteris Technologies Global Corp., Annual General Meeting, Dec 03, 2025Anteris Technologies Global Corp., Annual General Meeting, Dec 03, 2025.お知らせ • Oct 15Anteris Technologies Global Corp. Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal TrialAnteris Technologies Global Corp. announced it has received regulatory clearance from the Danish Medicines Agency to initiate the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calcific aortic stenosis (the "PARADIGM Trial"). Patient recruitment at Danish centers is expected to begin in fourth quarter 2025. With the first regulatory clearance secured, Anteris is positioned to drive the global PARADIGM Trial through the addition of further countries and sites in the near term, with planned expansion across the United States, Europe and Canada. In parallel, an Investigational Device Exemption (IDE) application remains under review by the U.S. Food and Drug Administation (FDA). Anteris continues to expect FDA approval in the near term, which will allow initiation of study sites in the PARADIGM Trial in the United States, pending Institutional Review Board (IRB) approval. The PARADIGM Trial is a prospective randomized controlled trial (RCT) which will evaluate the safety and effectiveness of the DurAVR® THV compared to commercially available transcatheter aoric valve replacements (TAVRs). The planned expansion across other geographies includes additional cohorts. A Premarket Approval (PMA) application requires a high level of clinical evidence to demonstrate reasonable assurance of safety and effectiveness for the intended use. Randomized controlled trials are generally considered Level 1 evidence, the highest level for determining the effectiveness of interventions in evidence-based medicine given RCTs minimize bias and allow a clear comparison between treatment groups.お知らせ • Jun 30+ 5 more updatesAnteris Technologies Global Corp.(NasdaqGM:AVR) dropped from Russell 2000 Value IndexAnteris Technologies Global Corp.(NasdaqGM:AVR) dropped from Russell 2000 Value Indexお知らせ • Jun 10Anteris Technologies Global Corp. Announces Board ChangesAnteris Technologies Global Corp. announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its board of directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. Mr. David Roberts is currently President of LeMaitre Vascular Inc., a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular Inc., Lexington Medical Inc. and Parasole Restaurant Holdings Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon’s $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in third quarter 2025 towards the ultimate U.S. and EMA licensure of the DurAVRTHV for patients with aortic stenosis.お知らせ • Mar 31Anteris Technologies Global Corp. Announces 100 Patients Treated with DurAVR THVAnteris Technologies Global Corp. announced a significant milestone in their mission to restore heart valve patients to healthy function. Their first in class, biomimetic DurAVR. Transcatheter Heart Valve has now been used to treat over 100 patients worldwide, marking a major achievement in their goal to revolutionize cardiac care in patients affected by severe aortic stenosis. Highlights: Over 100 patients successfully treated with the DurAVR THV, including de novo (first time) aortic stenosis cases, valve-in-valve patients and complex anatomies such as bicuspid aortic valve patients. 65 patients have successfully completed the primary endpoint measures of safety and efficacy, including hemodynamic benefit at 30-days post implant. One-year efficacy data on 37 aortic stenosis patients continues to validate the exceptional hemodynamic performance, with sustained large effective orifice areas and low mean pressure gradients. Excellent safety profile demonstrated at one-year, with no valve or cardiovascular related mortality. Range of valve sizes used to accommodate a broad patient population. The Company remains on track to commence the DurAVR THV Pivotal Trial in the third quarter of 2025, pending U.S. Food and Drug Administration approval.お知らせ • Mar 21Anteris Technologies Global Corp. Reports One-Year Patient Outcomes for DurAVR®? THVAnteris Technologies Global Corp. announced one-year results for patients treated with its proprietary, balloon expandable, DurAVR®? Transcatheter Heart Valve (THV) System. One-year Results Highlights: DurAVR®? THV demonstrated a favorable hemodynamic profile sustained to one-year, with an Effective Orifice Area (EOA) of 2.1 + 0.2 cm2, a Mean Pressure Gradient (MPG) of 8.6 + 2.6 mmHg and Doppler Velocity Index (DVI) of 0.58. At one-year, clinical safety outcomes show positive results with no valve or cardiovascular related mortality and importantly no prosthesis-patient mismatch (PPM) reported in these small annuli patients (aortic annulus area 395.80 + 37.26mm2). Current commercial devices have demonstrated rates between 11.2% to 35.3% PPM1, a predictor of valve failure and disease progression. Sixty-five (65) patients have completed the primary endpoint measure at 30 days (pre previously reported as rolling cohorts at multiple medical conferences through 2023-2024). The DurAVR®? TH V System continues to demonstrate a consistent safety and efficacy profile, with high implant success across the clinical program. The one-year data builds on the existing body of clinical evidence and will be included in the planned Investigational Device Exemption (IDE) submission to the U.S. FDA to seek approval to conduct the DurAVR®? THR®? THV randomized, global pivotal study.お知らせ • Mar 06Anteris Technologies Global Corp. Appoints David St Denis as President and as a Class II Director of the BoardAnteris Technologies Global Corp. advised that on 6 March 2025 the Board of Directors (the "Board") appointed David St Denis as the Company's President and as a Class II director of the Board, effective immediately. As a non-independent director, Mr. St Denis will not serve on any committees of the Board. Mr. St Denis, 56, has served as Chief Operating Officer of the Company since July 2017 and the Chief Executive Officer of v2vmedtech, inc. since April 2023. Mr. St Denis also served as Chief Financial Officer of v2vmedtech from April 2023 to September 2023. Prior to his appointment as Chief Operating Officer of the Company, Mr. St Denis served as Head of Commercial Operations for Europe and Canada at Merck since 2013, and prior to that served as Head of Operations for Emerging Markets at Merck since 2008. In addition, Mr. St Denis had held multiple leadership roles at Millennium Pharmaceuticals, Inc, now Takeda Pharmaceutical Company, from 1996 to 2006, and provided strategic consulting services to such company from 2006 to 2008. Mr. St Denis has a Bachelor of Science from the University of Connecticut, a Master of Arts from Boston University and an MBA in Global Management and International Marketing from Babson College--Franklin W. Olin Graduate School of Business. There are no arrangements or understandings between Mr. St Denis and any other persons pursuant to which Mr. St Denis was named as President of the Company or a director of the Board. There are no family relationships between Mr. St Denis and any director or executive officer of the Company. Mr. St Denis has no direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended. In connection with his previous appointment as Chief Operating Officer, the Company entered into its standard form of indemnification agreement for directors and officers with Mr. St Denis, which requires the Company to indemnify him against certain liabilities that may arise as a result of his status or service as a director or officer.お知らせ • Dec 27Anteris Technologies Ltd. Ordinary Shares to Be Deleted from OTC EquityAnteris Technologies Ltd. Ordinary Shares will be deleted from OTC Equity effective December 27, 2024, due to CUSIP Suspended.お知らせ • Dec 14Anteris Technologies Global Corp. has completed an IPO in the amount of $88.8 million.Anteris Technologies Global Corp. has completed an IPO in the amount of $88.8 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,800,000 Price\Range: $6 Discount Per Security: $0.42 Transaction Features: Sponsor Backed Offering収支内訳Anteris Technologies Global の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqGM:AVR 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 262-95277031 Dec 252-94266930 Sep 252-84256330 Jun 252-84266031 Mar 252-82275631 Dec 243-76285130 Sep 243-71254830 Jun 243-60224231 Mar 242-52193531 Dec 233-46173130 Sep 233-39182330 Jun 233-36201831 Mar 233-33221431 Dec 223-3023930 Sep 224-2520830 Jun 225-2419831 Mar 226-2217731 Dec 216-1714630 Sep 215-1513530 Jun 215-1512431 Mar 215-1312431 Dec 205-1213430 Sep 206-615330 Jun 207018331 Mar 208-217231 Dec 1912-421230 Sep 1914-1020230 Jun 1917-1721231 Mar 1917-1721231 Dec 1818-1721231 Dec 1718-1321130 Jun 1717-915131 Mar 1716-1116231 Dec 1614-1315230 Sep 1613-1617330 Jun 1611-1818431 Mar 1610-2018431 Dec 159-2016330 Sep 158-19152質の高い収益: AVRは現在利益が出ていません。利益率の向上: AVRは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: AVRは利益が出ておらず、過去 5 年間で損失は年間37.7%の割合で増加しています。成長の加速: AVRの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: AVRは利益が出ていないため、過去 1 年間の収益成長をMedical Equipment業界 ( 15.6% ) と比較することは困難です。株主資本利益率高いROE: AVRは現在利益が出ていないため、自己資本利益率 ( -34.19% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/09 02:31終値2026/08/07 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Anteris Technologies Global Corp. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Matthew MiksicBarclaysJohn HesterBell PotterRoss OsbornCantor Fitzgerald & Co.5 その他のアナリストを表示
お知らせ • Jun 29+ 5 more updatesAnteris Technologies Global Corp.(NasdaqGM:AVR) dropped from Russell Microcap Growth Benchmark IndexAnteris Technologies Global Corp.(NasdaqGM:AVR) dropped from Russell Microcap Growth Benchmark Index
Board Change • Jun 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Gregory Moss was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 09Anteris Technologies Global Corp. Receives French Regulatory Clearance for Duravr Transcatheter Heart Valve Global Pivotal TrialAnteris Technologies Global Corp. had received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) for the DurAVR Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calcific aortic stenosis (the PARADIGM Trial). This authorization marks a significant milestone in the Company’s clinical and regulatory strategy and enables patient recruitment to commence at centers in France. The Company continues to advance its global clinical strategy, with ongoing site activations and patient enrollment across the United States and Europe. The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR Transcatheter Heart Valve compared to commercially available transcatheter aortic valve replacements (TAVRs). This head-to-head study will enroll approximately 1,000 patients in the ‘All Comers Randomized Cohort’ with 1:1 randomization of patients who will receive either the DurAVR THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure. Anteris’ lead product, the DurAVR THV, was designed in collaboration with interventional cardiologists and cardiac surgeons to treat aortic stenosis – a condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT tissue, Anteris’ patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR Delivery System.
お知らせ • May 23Anteris Technologies Global Corp. has filed a Follow-on Equity Offering in the amount of $250 million.Anteris Technologies Global Corp. has filed a Follow-on Equity Offering in the amount of $250 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • May 14Anteris Technologies Global Corp. Appoint Board of DirectorAnteris Technologies Global Corp. announced the appointment of Ms. Susan Knight and Mr. Stephen Denaro to serve on the Board of Directors. Ms. Knight will serve as a Class I Director, with a term expiring at the Company's 2028 annual meeting of stockholders and will serve on the Audit and Risk Committee of the Board. Mr. Denaro will serve as a Class II Director, with a term expiring at the Company’s 2026 annual meeting of stockholders. Ms. Knight most recently served as the Board Chair of Surmodics Inc., a medical device provider, a position she held from 2015 until November 2025. She has served on corporate boards of directors since 2008 and has broad audit committee experience, including serving as committee chair at Surmodics Inc., Greater Metropolitan Housing Corporation and Plato Learning. During her professional career, Ms. Knight was the Senior Vice President and Chief Financial Officer of MTS Systems Corporation from 2011 to 2014 and its Chief Financial Officer from 2001 to 2011. Prior to MTS Systems Corporation, Ms. Knight was the Vice President of Finance of the Home and Building Control Business of Honeywell Inc. from 1994 to 2001. She also held various other management and executive financial positions during her 24-year career at Honeywell Inc. Ms. Knight earned a BSBA in Accounting from Creighton University. Mr. Denaro rejoins the Board with deep knowledge of the Company and its strategic priorities. Together these appointments reinforce the Company’s governance and strategic capabilities as it advances its global clinical and commercial objectives towards the anticipated U.S. and EMA licensure of the DurAVR THV for patients with aortic stenosis.
お知らせ • May 06Anteris Technologies Global Corp. Announces First U.S. Patients Treated in Global Pivotal Paradigm TrialAnteris Technologies Global Corp. announced that the first patients in the United States have been enrolled and successfully treated in the DurAVR Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the PARADIGM Trial). The procedures were performed at Montefiore Medical Center, New York, United States. The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR THV compared to commercially available transcatheter aortic valve replacements (TAVRs). This head-to-head study will enroll approximately 1,000 patients in the ‘All Comers Randomized Cohort’ with 1:1 randomization of patients who will receive either the DurAVR THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure. Anteris’ lead product, the DurAVR THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT tissue, Anteris’ patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR Delivery System.
お知らせ • Apr 29Anteris Technologies Global Corp. Secures Cms Reimbursement Eligibility for Paradigm TrialAnteris Technologies Global Corp. announced it has secured U.S. Medicare reimbursement eligibility for the global pivotal PARADIGM Trial under a Centers for Medicare & Medicaid Services (CMS) national coverage policy. Eligible procedures performed at participating U.S. study sites are covered under the Transcatheter Aortic Valve Replacement (TAVR) National Coverage Determination 20.32. The CMS framework operates under a Coverage with Evidence Development (CED) model, enabling reimbursement with clinical evidence generation in the PARADIGM Trial. The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR® Transcatheter Heart Valve (THV) compared to commercially available transcatheter aortic valve replacements (TAVRs). This head-to-head study will enroll approximately 1,000 patients in the ‘All Comers Randomized Cohort’ with 1:1 randomization of patients who will receive either the DurAVR® THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure. Anteris’ lead product, the DurAVR® THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
Seeking Alpha • Apr 23Anteris Technologies Looks Bullish If DurAVR's PARADIGM DeliversSummary Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in over 130 patients. AVR’s PARADIGM pivotal trial is the central catalyst. This will compare DurAVR against commercial valves across 85 sites in the US, Europe, and Canada. I believe that Medtronic’s 16.2% stake also offers strategic validation of AVR’s underlying valve technology. And, after AVR’s recent raises, its balance sheet seems well capitalized despite ongoing cash burn. AVR remains speculative until they receive full regulatory approvals. But I feel the upside potential justifies those risks in the long run. Read the full article on Seeking Alpha
お知らせ • Jan 22Anteris Technologies Global Corp. has completed a Follow-on Equity Offering in the amount of $200.000002 million.Anteris Technologies Global Corp. has completed a Follow-on Equity Offering in the amount of $200.000002 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 34,782,609 Price\Range: $5.75 Discount Per Security: $0.29325
お知らせ • Jan 21+ 1 more updateAnteris Technologies Global Corp. has filed a Follow-on Equity Offering in the amount of $319.999995 million.Anteris Technologies Global Corp. has filed a Follow-on Equity Offering in the amount of $319.999995 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 55,652,173 Price\Range: $5.75 Discount Per Security: $0.29325
お知らせ • Dec 15Anteris Technologies Global Corp. Announces Resignation of Stephen Denaro from the Board of DirectorsAnteris Technologies Global Corp. announced on December 14, 2025, Mr. Stephen Denaro resigned from the Board of Directors (the "Board") of Anteris Technologies Global Corp. (the "Company") and as a Class II director with immediate effect. The resignation from the Board was not due to any disagreement with the Company or its management with respect to any matter relating to the Company's operations, policies or practices. Mr. Denaro will continue to serve as the corporate secretary of Anteris Technologies Pty Ltd. ("ATPL") and as a member of the Board of Directors of ATPL and the Company's other Australian subsidiaries.
お知らせ • Nov 18Anteris Technologies Global Corp. Presents Data from 100 DurAVR®? THV Patients at PCR London ValvesAnteris Technologies Global Corp. released 30-day clinical outcomes for the DurAVR®? THV in one hundred severe aortic stenosis patients with small aortic annuli (aortic annulus area 404 +- 37mm2). TheDurAVR®? THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality, with 97% freedom from moderate or severe paravalvulvular leak (PPM) in a cohort of small annuli patients similar to the one reported in the SMART Trial1. 30-day Results Highlights for 100 DurAVR®?THV Patients: DurAVR®? TH V delivered a favorable hemodynamic profile with a large EOA of 2.2 +- 0.3 cm2 and a single digit mean pressure gradient (MPG) of 8.2 +- 3.1 mmHg. At 30-days, clinical safety outcomes were positive with no valve related mortality and no moderate or severe paravalVular leak (PVL). Prosthesis-patient mismatch was just 3.0% compared with 11.2% to 35.3% for current commercial devices, highlighting a meaningful reduction in a key predictor of valve failure and disease progression. Hahn RT, Pibarot P. Prosthesis-patient mismatch in transcatheter and surgical aortic valve replacement.
お知らせ • Nov 06Anteris Technologies Global Corp. has completed a Follow-on Equity Offering in the amount of AUD 20.91048 million.Anteris Technologies Global Corp. has completed a Follow-on Equity Offering in the amount of AUD 20.91048 million. Security Name: CHESS Depositary Interests Security Type: Depositary Receipt (Common Stock) Securities Offered: 2,788,064 Price\Range: AUD 7.5 Discount Per Security: AUD 0.45 Security Features: Attached Warrants Transaction Features: Regulation S; Subsequent Direct Listing
お知らせ • Nov 04FDA Approves Anteris Technologies Global Corp.'s DurAVR®? THV Global Pivotal TrialAnteris Technologies Global Corp. announced it has received U.S. Food and Drug Administration (FDA) approval to initiate PARADIGM, its global Investigational Device Exemption (IDE) clinical trial which is designed to evaluate the DurAVR®? Transcatheter Heart Valve (THV) in patients with severe calcific aortic stenosis and to support a future PMA submission. The PARADIGM Trial is co-chaired by Dr. Michael J. Reardon, Allison Family Distinguished Chair of Cardiovascular Research and Professor of Cardiothoracic Surgery at the Houston Methodist Hospital, Texas and Professor Stephan Windecker, Chairman of the Department of Cardiology at Bern University Hospital, Switzerland. The PARADIGM trial is a prospective randomized controlled trial (RCT) which will evaluate the safety and effectiveness of the DurAVR®? THV compared to commercially available transcatheter aortic valve replacements (TAVRs). This head-to-head study will enroll approximately 1000 patients across the Unites States, Europe and Canada in the 'All Comers Randomized Cohort' with 1:1 randomization of patients who will receive either the DurAVR®?THV or TAVR®? using commercially available and approved THVs. The PARADigM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure. The PARADIGM trials is designed to provide the robust clinical evidence required to support an application to the FDA for Premarket Approval in the United States, with CE Mark approval anticipated to progress in parallel to the PMA. A Premarket Approval (PMA) application requires a high level of clinical evidence to demonstrate reasonable assurance of safety and effectiveness for the intended use. Randomized controlled trials are generally considered Level 1 evidence, the highest level for determining the effectiveness of interventions in evidence-based medicine given RCTs minimize bias and allow a clear comparison between treatment groups.
お知らせ • Oct 29Anteris Technologies Global Corp. Announces One-Year Clinical Outcomes for the DurAVR Transcatheter Heart ValveAnteris Technologies Global Corp. announced one-year clinical outcomes for the DurAVR®? Transcatheter Heart Valve (THV) in symptomatic severe aortic stenosis patients with small aortic annulus area 396 + 37 mm2). The DurAVR®? THV System demonstrated single digit mean gradients and large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality at one year, with low prosthesis-patient mismatch at 30 days. One-year Results Highlights: DurAVR®?THV delivered a favorable hemodynamic profile sustained to one-year, with an EOA of 2.1 + 0.2 cm2 and a mean pressure gradient (MPG) of 8.6 + 2.6 mmHg. At one-year, clinical safety outcomes were positive with no valve related mortality and no moderate or severe paravalVular leak (PVL). At 30-days, prosthesis-patient mismatch was just 1.5%, compared with 11.2% to 35.3%1 for current commercial devices, highlighting a meaningful reduction in a key predictor of valve failure and disease progression. The pooled cohort included 65 patients with small aortic Annuli implanted with the DurAVR®? TH V from the ongoing EBARK Study and US Early Feasibility Study (EFS). The encouraging clinical outcomes observed to date in over 100 patients implanted with the DurAVR™? THV will be further validated in the Company's recently initiated global pivotal trial (the "PARADIGM Trial"). The PARADIGM Trial (ClinicalTrials.gov ID NCT07194265) is a prospective, randomized controlled trial (RCT) which will evaluate the safety and effectiveness of theDurAVR®? THV compared to commercially available transcatheter aortic valve replacements (TAVRs) in the treatment of severe aortic stenosis. Prosthesis-patient mismatch (PPM) happens when a prosthetic valve, after being implanted, doesn't have a large enough opening (EOA) to accommodate the patient's blood flow needs, based on their body size. The result is higher than expected gradients. PPM affects a significant proportion of transcatheter aortic valves (TAVR) patients, particularly patients with a small aortic annulus and has been associated with impaired long-term survival following surgical aortic valve replacement (SAVR).
お知らせ • Oct 28+ 2 more updatesAnteris Technologies Global Corp. announced that it has received $11.499986 million in fundingOn October 27, 2025, Anteris Technologies Global Corp closed the transaction.
お知らせ • Oct 16Anteris Technologies Global Corp., Annual General Meeting, Dec 03, 2025Anteris Technologies Global Corp., Annual General Meeting, Dec 03, 2025.
お知らせ • Oct 15Anteris Technologies Global Corp. Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal TrialAnteris Technologies Global Corp. announced it has received regulatory clearance from the Danish Medicines Agency to initiate the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calcific aortic stenosis (the "PARADIGM Trial"). Patient recruitment at Danish centers is expected to begin in fourth quarter 2025. With the first regulatory clearance secured, Anteris is positioned to drive the global PARADIGM Trial through the addition of further countries and sites in the near term, with planned expansion across the United States, Europe and Canada. In parallel, an Investigational Device Exemption (IDE) application remains under review by the U.S. Food and Drug Administation (FDA). Anteris continues to expect FDA approval in the near term, which will allow initiation of study sites in the PARADIGM Trial in the United States, pending Institutional Review Board (IRB) approval. The PARADIGM Trial is a prospective randomized controlled trial (RCT) which will evaluate the safety and effectiveness of the DurAVR® THV compared to commercially available transcatheter aoric valve replacements (TAVRs). The planned expansion across other geographies includes additional cohorts. A Premarket Approval (PMA) application requires a high level of clinical evidence to demonstrate reasonable assurance of safety and effectiveness for the intended use. Randomized controlled trials are generally considered Level 1 evidence, the highest level for determining the effectiveness of interventions in evidence-based medicine given RCTs minimize bias and allow a clear comparison between treatment groups.
お知らせ • Jun 30+ 5 more updatesAnteris Technologies Global Corp.(NasdaqGM:AVR) dropped from Russell 2000 Value IndexAnteris Technologies Global Corp.(NasdaqGM:AVR) dropped from Russell 2000 Value Index
お知らせ • Jun 10Anteris Technologies Global Corp. Announces Board ChangesAnteris Technologies Global Corp. announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its board of directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. Mr. David Roberts is currently President of LeMaitre Vascular Inc., a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular Inc., Lexington Medical Inc. and Parasole Restaurant Holdings Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon’s $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in third quarter 2025 towards the ultimate U.S. and EMA licensure of the DurAVRTHV for patients with aortic stenosis.
お知らせ • Mar 31Anteris Technologies Global Corp. Announces 100 Patients Treated with DurAVR THVAnteris Technologies Global Corp. announced a significant milestone in their mission to restore heart valve patients to healthy function. Their first in class, biomimetic DurAVR. Transcatheter Heart Valve has now been used to treat over 100 patients worldwide, marking a major achievement in their goal to revolutionize cardiac care in patients affected by severe aortic stenosis. Highlights: Over 100 patients successfully treated with the DurAVR THV, including de novo (first time) aortic stenosis cases, valve-in-valve patients and complex anatomies such as bicuspid aortic valve patients. 65 patients have successfully completed the primary endpoint measures of safety and efficacy, including hemodynamic benefit at 30-days post implant. One-year efficacy data on 37 aortic stenosis patients continues to validate the exceptional hemodynamic performance, with sustained large effective orifice areas and low mean pressure gradients. Excellent safety profile demonstrated at one-year, with no valve or cardiovascular related mortality. Range of valve sizes used to accommodate a broad patient population. The Company remains on track to commence the DurAVR THV Pivotal Trial in the third quarter of 2025, pending U.S. Food and Drug Administration approval.
お知らせ • Mar 21Anteris Technologies Global Corp. Reports One-Year Patient Outcomes for DurAVR®? THVAnteris Technologies Global Corp. announced one-year results for patients treated with its proprietary, balloon expandable, DurAVR®? Transcatheter Heart Valve (THV) System. One-year Results Highlights: DurAVR®? THV demonstrated a favorable hemodynamic profile sustained to one-year, with an Effective Orifice Area (EOA) of 2.1 + 0.2 cm2, a Mean Pressure Gradient (MPG) of 8.6 + 2.6 mmHg and Doppler Velocity Index (DVI) of 0.58. At one-year, clinical safety outcomes show positive results with no valve or cardiovascular related mortality and importantly no prosthesis-patient mismatch (PPM) reported in these small annuli patients (aortic annulus area 395.80 + 37.26mm2). Current commercial devices have demonstrated rates between 11.2% to 35.3% PPM1, a predictor of valve failure and disease progression. Sixty-five (65) patients have completed the primary endpoint measure at 30 days (pre previously reported as rolling cohorts at multiple medical conferences through 2023-2024). The DurAVR®? TH V System continues to demonstrate a consistent safety and efficacy profile, with high implant success across the clinical program. The one-year data builds on the existing body of clinical evidence and will be included in the planned Investigational Device Exemption (IDE) submission to the U.S. FDA to seek approval to conduct the DurAVR®? THR®? THV randomized, global pivotal study.
お知らせ • Mar 06Anteris Technologies Global Corp. Appoints David St Denis as President and as a Class II Director of the BoardAnteris Technologies Global Corp. advised that on 6 March 2025 the Board of Directors (the "Board") appointed David St Denis as the Company's President and as a Class II director of the Board, effective immediately. As a non-independent director, Mr. St Denis will not serve on any committees of the Board. Mr. St Denis, 56, has served as Chief Operating Officer of the Company since July 2017 and the Chief Executive Officer of v2vmedtech, inc. since April 2023. Mr. St Denis also served as Chief Financial Officer of v2vmedtech from April 2023 to September 2023. Prior to his appointment as Chief Operating Officer of the Company, Mr. St Denis served as Head of Commercial Operations for Europe and Canada at Merck since 2013, and prior to that served as Head of Operations for Emerging Markets at Merck since 2008. In addition, Mr. St Denis had held multiple leadership roles at Millennium Pharmaceuticals, Inc, now Takeda Pharmaceutical Company, from 1996 to 2006, and provided strategic consulting services to such company from 2006 to 2008. Mr. St Denis has a Bachelor of Science from the University of Connecticut, a Master of Arts from Boston University and an MBA in Global Management and International Marketing from Babson College--Franklin W. Olin Graduate School of Business. There are no arrangements or understandings between Mr. St Denis and any other persons pursuant to which Mr. St Denis was named as President of the Company or a director of the Board. There are no family relationships between Mr. St Denis and any director or executive officer of the Company. Mr. St Denis has no direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended. In connection with his previous appointment as Chief Operating Officer, the Company entered into its standard form of indemnification agreement for directors and officers with Mr. St Denis, which requires the Company to indemnify him against certain liabilities that may arise as a result of his status or service as a director or officer.
お知らせ • Dec 27Anteris Technologies Ltd. Ordinary Shares to Be Deleted from OTC EquityAnteris Technologies Ltd. Ordinary Shares will be deleted from OTC Equity effective December 27, 2024, due to CUSIP Suspended.
お知らせ • Dec 14Anteris Technologies Global Corp. has completed an IPO in the amount of $88.8 million.Anteris Technologies Global Corp. has completed an IPO in the amount of $88.8 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,800,000 Price\Range: $6 Discount Per Security: $0.42 Transaction Features: Sponsor Backed Offering